Biotech Co. Sued In Delaware Over 'Excessive' Director Pay
Directors of small-cap, clinical stage biopharmaceutical company Y-mAbs Therapeutics Inc. have been hit with a stockholder derivative suit challenging and seeking recovery of non-employee board compensation described as far exceeding awards...To view the full article, register now.
Already a subscriber? Click here to view full article